Plain-English translation of NCT07477990 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a digital medical device called Aurora® that provides cognitive behavioral therapy (a proven talk-therapy approach) combined with standard anxiety medications. The study wants to know whether using Aurora® along with medication like escitalopram or duloxetine reduces anxiety symptoms more effectively than taking medication alone. About 162 adults with moderate to severe anxiety will participate.
Current anxiety treatments help many people, but some patients still struggle with significant symptoms. This trial is exploring whether combining a digital therapy tool with standard medication might be more effective than medication by itself.
You likely qualify if…
You likely don't qualify if…
Half of the participants will take their prescribed anxiety medication and also use the Aurora® digital app on a device like a phone or tablet to complete therapy sessions over 12 weeks. The other half will take the same medication without the app. Throughout the study, you'll have appointments where your anxiety symptoms are measured using a standard questionnaire to see how much improvement you've experienced.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Mexico